Agunan Krishnan

Agunan Krishnan is a seasoned professional in business development and corporate strategy, currently serving as the Director of Business Development at Jubilant Therapeutics Inc since July 2019. Prior roles include Associate Director and Senior Manager of Business Development at the same company, as well as Manager of Corporate Strategy at Jubilant Biosys, where notable achievements included leading the out-licensing of a BET inhibitors program to CheckPoint Therapeutics and facilitating a significant out-licensing deal valued at $180 million. Agunan Krishnan's educational background includes a Post Graduate degree in Molecular Biology from the University of Staffordshire and a Bachelor's degree in Veterinary Medicine from Tamil Nadu Veterinary and Animal Sciences University.